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Abstract
Background Conventional lymphoscintigraphy does not
always deﬁne the exact anatomic location of a sentinel
node. The lymphatic drainage pattern may be unusual or
may not be shown at all. The recently introduced hybrid
SPECT/CT imaging could help overcome these difﬁculties.
SPECT is a tomographic version of conventional lympho-
scintigraphy and the images have better contrast and
resolution. When fusedwith the anatomical details provided
by CT into one image, a meaningful surgical ‘‘roadmap’’
can be created. So far, there is little literature on the use of
hybrid SPECT/CT in lymphatic mapping in patients with
breast cancer. The purpose of this review was to report on
these publications, including our own experience, focusing
on patient selection, SPECT/CT settings, anatomic locali-
zation, and the detection of additional sentinel nodes.
Methods The majority of investigators did not formulate
indications for additional SPECT/CT after conventional
imaging but scanned all patients eligible for sentinel node
biopsy. The SPECT/CT settings used in the studies of this
review were mostly similar, but the methods used for
conventional imaging were more variable.
Results All studies demonstrated an improved anatomical
localization by performing additional SPECT/CT; sentinel
nodes outside the axilla or nodes close to the injection site
were especially easier to identify. Sentinel nodes were
visualized in 89–100% by combined conventional imaging
and SPECT/CT, with sentinel nodes depicted only by
SPECT/CT in up to 14%.
Conclusion It is concluded that SPECT/CT shows the
exact anatomical location of sentinel nodes, detects senti-
nel nodes not depicted by conventional imaging, and
therefore facilitates surgical exploration. The hybrid
SPECT/CT has the potential to make image fusion a rou-
tine clinical tool that improves lymphatic mapping in
patients with breast cancer.
Introduction
Conventional lymphoscintigraphy does not always deﬁne
the exact anatomic location of a sentinel node [1–4]. Lym-
phatic drainage may follow anunusualpatternormay notbe
shown at all on conventional images. The intraoperative use
of blue dye and a hand-held gamma-ray detection probe still
enables identiﬁcation of the sentinel node in many of such
patients but not in all of them [5]. A noninvasive technique
that allows for an improved preoperative sentinel node
localization and detection rate would be helpful.
The combination of a SPECT (single-photon emission
computed tomography) camera and a CT integrates phys-
iologic and anatomic information [6]. SPECT is a
tomographic version of conventional scintigraphy, in this
case lymphoscintigraphy, but with a better contrast and
resolution. In combination with the anatomical details
provided by CT, a meaningful roadmap for the surgeon can
be obtained.
Initially, attempts were made to combine separately
performed SPECT and CT images after acquisition of these
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patient preparation and mathematical modeling made
proper alignment of the two techniques too time-consum-
ing for a routine procedure.
The recently introduced hybrid SPECT/CT unites both
imaging techniques in one device, which is beneﬁcial in
several ways [9–11]. Special computer software and
external fusion landmarks are redundant. The position of
the patient does not need to be changed, which avoids
possible errors in image alignment caused by movement of
internal organs. Scatter and attenuation induced by the
generation or fusion of the SPECT and CT images also can
be corrected.
So far, the available literature on the use of a hybrid
SPECT/CT in lymphatic mapping in patients with cancer is
limited. The purpose of this literature study was to review
the publications that have explored the additional value of
SPECT/CT in lymphatic mapping in patients with breast
cancer, including our own experience, focusing on patient
selection, SPECT/CT settings, anatomic localization, and
the detection of additional sentinel nodes.
Methods
The databases PubMed, Embase, and the Cochrane Library
were searched for studies concerning patients with breast
cancer who underwent SPECT/CT for lymphatic mapping.
The following medical subject headings (MeSH) terms
were used to ﬁnd relevant articles: ‘‘breast neoplasms’’;
‘‘sentinel lymph node biopsy’’; and ‘‘tomography, emis-
sion-computed, single-photon.’’ All data concerning patient
selection, SPECT/CT settings, anatomic localization, and
the detection of additional sentinel nodes were analyzed.
Results
Four studies were published between March 2006 and
November 2007, which described a total of 449 patients, of
which 351 are described in this article (Tables 1 and 2)
[12–15]. Lerman et al. has twice published on the use of
SPECT/CT in lymphatic mapping in patients with breast
cancer [13, 14]. The ﬁrst publication is included in this
report and only the overweight patient group from the
second publication, because the remaining patients had
already been described in the ﬁrst paper. SPECT/CT was
used for lymphatic mapping in consecutive patients with
breast cancer in three institutes [12–14]. Lerman et al. [14]
described the additional value in the above-mentioned
subgroup of overweight patients. Van der Ploeg et al. [15]
performed SPECT/CT only as additional technique in dif-
ﬁcult cases, such as conventional images with lymphatic
drainage to nodes outside the axilla, sentinel nodes close to
the injection site, or images without a sentinel node.
SPECT/CT was performed without reinjection of the
radiopharmaceutical in this study.
The protocols for conventional imaging differed from
each other (Table 1). Dosages of 74 MBq to 120 MBq
99mTc-labeled tracers were administered into or around the
tumor and early imaging was performed. Additional late
images were obtained in three of the four studies. All
papers described the use of a hybrid SPECT/CT with a
low-dose CT. A 2-day protocol was used with lympho-
scintigraphy on the ﬁrst day and the operation on the
second. The SPECT settings and acquisition times men-
tioned in the papers were similar (Table 2). All groups of
investigators performed SPECT/CT after conventional
imaging and corrected for attenuation and scatter.
All four papers mention improved anatomical localiza-
tion by performing additional SPECT/CT after
conventional imaging [12–15]. Husarik et al. [12] describe
that SPECT/CT provided more accurate anatomical infor-
mation in 82% of patients and was conclusive in exact
anatomical information in 70%. SPECT/CT also discov-
ered additional sites of lymphatic drainage not depicted by
conventional scans. Overall, sentinel nodes were visualized
on conventional images in 72–94% of the patients and in
89–100% when SPECT/CT was added. The improvement
was most pronounced in problematic cases. In 4–14% of
Table 1 Patients and methods of conventional imaging
Study Date No. of
patients
Indication Dosage and radiotracer Injection
site
Conventional imaging
Lerman et al. [13] March 2006 157 T0-2N0M0 74 MBq
99mTc-rhenium colloid PT or IT 60 min up to 24 hr p.i.
Husarik et al. [12] January 2007 41 T0-2N0M0 80 MBq
99mTc-nanocolloid PT and ID 30 min p.i.
Lerman et al. [14] Febraury 2007 122 Overweight patients 74 MBq
99mTc-rhenium colloid PT or IT 60 min up to 24 hr p.i.
Van der Ploeg
et al. [15]




99mTc-nanocolloid IT 15 min, 2, 4 hr p.i.
a Conventional images that were difﬁcult to interpret, such as sentinel nodes outside the axilla or nonvisualization
PT peritumoral, IT intratumoral, ID intradermal, p.i. postinjection
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123the patients, sentinel nodes were depicted only by SPECT/
CT (Fig. 1). In the study by Van der Ploeg et al. [15], 17%
of sentinel nodes visualized only by SPECT/CT were
tumor-positive, which led to upstaging in these patients and
changed their management. The additional sentinel nodes
were depicted close to the radiopharmaceutical injection
site, in the internal mammary chain, in the breast or
between the pectoral muscles. In patients with internal
mammary sentinel nodes, SPECT/CT can show the exact
intercostal space or a location behind a rib (Fig. 2)[ 15].
SPECT/CT was able to distinguish two sentinel nodes from
one another when depicted as one node on conventional
images. Two papers mention that 4–17% of the hot spots
detected on conventional scans were mistaken for nodes
but were accurately classiﬁed by SPECT/CT as non-nodal
sites of uptake [12, 13]. These false-positive sites of uptake
were mostly the result of contamination of the skin with the
radiopharmaceutical or the injection site was mistaken for a
sentinel node. Lerman et al. [13] reported one patient
(0.6%) with a tumor-positive sentinel node that was visu-
alized by conventional imaging and not depicted by
SPECT/CT.
Discussion
Sentinel node biopsy in patients with clinically node-neg-
ative breast cancer is a valuable procedure for nodal
staging. It allows the detection of clinically occult metas-
tases by a meticulous histopathological examination, which
may indicate the need for further treatment [16–18].
Accurate visualization of the sentinel nodes is required for
the best results. Based on the concept of stepwise spread of
metastases through the lymphatic system, all visualized
nodes on a direct drainage pathway from the primary tumor
site are sentinel nodes and should be identiﬁed and
examined [19–21]. SPECT/CT was introduced in lympha-
tic mapping with the goal to show more sentinel nodes and
to show them more clearly than is possible with conven-
tional lymphoscintigraphy to improve nodal staging.
The SPECT/CT settings used in the studies in this review
were comparable, but the methods used for conventional
imaging were not always similar [12–15]. Especially the
timing and acquisition duration of conventional scans and
the timing of SPECT/CT imaging differed among the
studies. The majority of investigators did not formulate
indications for the use of SPECT/CT. SPECT/CT correlates
radiotracer accumulation with a morphologic structure.
Importantly, all four groups of investigators corrected for
attenuation and scatter for the SPECT and CT images.
All studies mentioned better anatomical localization by
performing additional SPECT/CT after conventional









Lerman et al. [13] Yes
a Matrix 128 9 128, 3- angle steps,
20/25 s time frame
25–28 84/91 13
Husarik et al. [12] Yes, 40 min p.i. Matrix 128 9 128, 3- angle steps,
20 s time frame
27 Not mentioned 14
Lerman et al. [14] Yes
a Matrix 512 9 512, 3- angle steps,
20/25 s time frame
25–28 72/89 Not mentioned
Van der Ploeg
et al. [15]
Yes, 4 hr p.i. Matrix 128 9 128, 6- angle steps,
25 s time frame
15 94/100 4
a SPECT/CT was presumably performed 60 minutes after radiopharmaceutical injection and sometimes before conventional imaging
CI conventional imaging, SN sentinel node, p.i. postinjection
Fig. 1 Woman with a left breast cancer. The conventional lym-
phoscintigraphic anterior (A) and lateral (B) images 4 hours after
radiopharmaceutical injection show no lymphatic drainage. The
transaxial SPECT/CT (C) depicts an axillary sentinel node (arrow)
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123imaging, which improved the surgical approach. Especially
sentinel nodes outside the axilla or nodes close to the
injection site were better located by performing additional
SPECT/CT. Sentinel nodes were visualized on conven-
tional images in 72–94% of the patients and these numbers
improved to 89–100% by adding SPECT/CT. Sentinel
nodes missed by conventional imaging were depicted by
SPECT/CT in up to 14% of the cases. SPECT/CT showed
that some sites of uptake that had been suggested to be
sentinel nodes by conventional imaging were in reality
something else, for example, sites of skin contamination
with the radiopharmaceutical.
Failure of lymphoscintigraphic imaging in the reviewed
papers might be caused by the technique that was used. For
example, the dosage, volume, or particle size of the radi-
otracer might not have been the perfect combination to
visualize all lymphatic drainage sites. The time of con-
ventional imaging after injection of the radiotracer might
not be ideal either. Some nuclear medicine physicians
stopped data acquisition after early imaging, which pre-
vents the visualization of sentinel nodes in case of slow
lymph ﬂow. SPECT/CT has been shown to improve the
visualization rate because of its better contrast and
resolution.
The introduction of the hybrid SPECT/CT in daily
practice is associated with extra costs and takes more time
because it is additional to conventional lymphoscintigra-
phy. We think that the advantages prevail if SPECT/CT is
used in problematic cases only.
Although the overall extent of the improvement ishard to
establish because of differences in methods and patient
selection, we conclude that the hybrid SPECT/CT takes
preoperative lymphoscintigraphy to a higher level and has
thepotentialtomakeimage-fusionaroutineclinicaltoolthat
will result in better staging of patients with breast cancer.
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